Jung Hwan Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jung Hwan Park has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Ho Jun Chin
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
4 shared publications - Hajeong Lee
Transplantation Center, Seoul National University Hospital, Seoul, Republic of Korea
2 shared publications - Ho Seok Koo
Department of Internal Medicine, Inje University College of Medicine, Busan, Republic of Korea
2 shared publications - Jieun Oh
Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea
2 shared publications Jong-Ho Lee
2 shared publicationsSuhnggwon Kim
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 6 March 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Early hemoglobin levels after kidney transplantation predict clinical outcomes
The impact of early hemoglobin levels following kidney transplantation (KT) on long-term outcomes remains unclear. This study evaluates the association between early posttransplant hemoglobin levels and clinical outcomes. A total of 7,501 kidney transplant recipients (KTRs) from a nationwide cohort were included. Hemoglobin levels at 6 months post-KT were analyzed. KTRs were categorized into five hemoglobin groups: <10, 10 to <11, 11 to <12, 12 to <13 (reference group), and ≥13 g/dL. The primary outcome was a composite of cardiovascular events, graft loss, and all-cause mortality. Multivariable Cox regression was employed to assess the relationship between hemoglobin levels and the composite outcome. The cohort had a mean age of 49.6 ± 11.6 years, and 60.4% were male. The incidence of the composite outcome and its individual components was highest among KTRs with hemoglobin levels <10 g/dL. Hemoglobin levels <10 g/dL were associated with a significantly increased risk of the composite outcome (hazard ratio [HR], 3.16; 95% confidence interval [CI], 2.05-4.87; p < 0.001) and were identified as an independent risk factor for each component. Conversely, hemoglobin levels ≥13 g/dL were associated with improved survival (HR, 0.44; 95% CI, 0.22-0.90; p = 0.02). Subgroup analyses confirmed that hemoglobin levels <10 g/ dL consistently increased the risk of the composite outcome. Posttransplant anemia with hemoglobin levels <10 g/dL showed a significant association with an increased risk of the composite outcome. Conversely, hemoglobin levels ≥13 g/dL were linked to better patient survival.
- 6 March 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Open AccessEarly hemoglobin levels after kidney transplantation predict clinical outcomes
The impact of early hemoglobin levels following kidney transplantation (KT) on long-term outcomes remains unclear. This study evaluates the association between early posttransplant hemoglobin levels and clinical outcomes. A total of 7,501 kidney transplant recipients (KTRs) from a nationwide cohort were included. Hemoglobin levels at 6 months post-KT were analyzed. KTRs were categorized into five hemoglobin groups: <10, 10 to <11, 11 to <12, 12 to <13 (reference group), and ≥13 g/dL. The primary outcome was a composite of cardiovascular events, graft loss, and all-cause mortality. Multivariable Cox regression was employed to assess the relationship between hemoglobin levels and the composite outcome. The cohort had a mean age of 49.6 ± 11.6 years, and 60.4% were male. The incidence of the composite outcome and its individual components was highest among KTRs with hemoglobin levels <10 g/dL. Hemoglobin levels <10 g/dL were associated with a significantly increased risk of the composite outcome (hazard ratio [HR], 3.16; 95% confidence interval [CI], 2.05-4.87; p < 0.001) and were identified as an independent risk factor for each component. Conversely, hemoglobin levels ≥13 g/dL were associated with improved survival (HR, 0.44; 95% CI, 0.22-0.90; p = 0.02). Subgroup analyses confirmed that hemoglobin levels <10 g/ dL consistently increased the risk of the composite outcome. Posttransplant anemia with hemoglobin levels <10 g/dL showed a significant association with an increased risk of the composite outcome. Conversely, hemoglobin levels ≥13 g/dL were linked to better patient survival.
- Open Access
- 31 March 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 44 (2) , 338-348
Immediate-start peritoneal dialysis without break-in-period: an 18-year retrospective cohort study on patient survival
Background: Immediate-start peritoneal dialysis (ISPD) is an effective renal replacement therapy that can prevent central venous catheterization due to its immediate initiation of peritoneal dialysis (PD) after catheter insertion without a break-in period. This study aimed to investigate the effect of ISPD on long-term patient survival. Methods: In this retrospective single-center cohort study, 178 consecutive patients who started PD from August 2005 to March 2023 were enrolled, from whom 144 patients with ISPD were analyzed. PD was initiated without a break-in period within 24 hours of catheter insertion using percutaneous needle-guidewire technique. The primary outcome was patient survival, estimated using the Kaplan-Meier method. A Cox proportional hazard regression model was used to identify factors independently associated with patient survival. Results: The median follow-up period was 4.00 years (interquartile range, 1.23–5.75 years). The mean age of patients was 61.6 ± 13.6 years; 58 patients (40.3%) were male and 93 patients (64.6%) were diabetic. Overall patient survival rates at 1, 3, 5, and 10 years were 98.5%, 93.5%, 92.1%, and 65.6%, respectively. The technique survival rates at 1, 3, 5, and 10 years were 88.1%, 74.9%, 63.2%, and 40.2%, respectively. The peritonitis-free survival rates at 1, 3, 5, and 10 years were 92.3%, 76.0%, 59.4%, and 28.0%, respectively. In the multivariate analysis, diabetes was the only factor associated with patient survival and technique survival. Conclusion: Our study demonstrated that patient survival and technique survival rates were relatively high in ISPD patients who were catheterized using percutaneous needle-guidewire technique.
- 31 March 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 44 (2) , 338-348
Open AccessImmediate-start peritoneal dialysis without break-in-period: an 18-year retrospective cohort study on patient survival
Background: Immediate-start peritoneal dialysis (ISPD) is an effective renal replacement therapy that can prevent central venous catheterization due to its immediate initiation of peritoneal dialysis (PD) after catheter insertion without a break-in period. This study aimed to investigate the effect of ISPD on long-term patient survival. Methods: In this retrospective single-center cohort study, 178 consecutive patients who started PD from August 2005 to March 2023 were enrolled, from whom 144 patients with ISPD were analyzed. PD was initiated without a break-in period within 24 hours of catheter insertion using percutaneous needle-guidewire technique. The primary outcome was patient survival, estimated using the Kaplan-Meier method. A Cox proportional hazard regression model was used to identify factors independently associated with patient survival. Results: The median follow-up period was 4.00 years (interquartile range, 1.23–5.75 years). The mean age of patients was 61.6 ± 13.6 years; 58 patients (40.3%) were male and 93 patients (64.6%) were diabetic. Overall patient survival rates at 1, 3, 5, and 10 years were 98.5%, 93.5%, 92.1%, and 65.6%, respectively. The technique survival rates at 1, 3, 5, and 10 years were 88.1%, 74.9%, 63.2%, and 40.2%, respectively. The peritonitis-free survival rates at 1, 3, 5, and 10 years were 92.3%, 76.0%, 59.4%, and 28.0%, respectively. In the multivariate analysis, diabetes was the only factor associated with patient survival and technique survival. Conclusion: Our study demonstrated that patient survival and technique survival rates were relatively high in ISPD patients who were catheterized using percutaneous needle-guidewire technique.
- Open Access
- 13 January 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (2) , 751
Comprehensive Analysis of Cardiac Xeno-Graft Unveils Rejection Mechanisms
Porcine heart xenotransplantation is a potential treatment for patients with end-stage heart failure. To understand molecular mechanisms of graft rejection after heart transplantation, we transplanted a 31-day-old alpha-1,3-galactosyltransferase knockout (GTKO) porcine heart to a five-year-old cynomolgus monkey. Histological and transcriptome analyses were conducted on xenografted cardiac tissue at rejection (nine days after transplantation). The recipient monkey’s blood parameters were analyzed on days −7, −3, 1, 4, and 7. Validation was conducted by quantitative real-time PCR (qPCR) with selected genes. A non-transplanted GTKO porcine heart from an age-matched litter was used as a control. The recipient monkey showed systemic inflammatory responses, and the rejected cardiac graft indicated myocardial infarction and cardiac fibrosis. The transplanted heart exhibited a total of 3748 differentially expressed genes compared to the non-transplanted heart transcriptome, with 2443 upregulated and 1305 downregulated genes. Key biological pathways involved at the terminal stage of graft rejection were cardiomyopathies, extracellular interactions, and ion channel activities. The results of qPCR evaluation were in agreement with the transcriptome data. Transcriptome analysis of porcine cardiac tissue at graft rejection reveals dysregulation of the key molecules and signaling pathways, which play relevant roles on structural and functional integrities of the heart.
- 13 January 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (2) , 751
Open AccessComprehensive Analysis of Cardiac Xeno-Graft Unveils Rejection Mechanisms
Porcine heart xenotransplantation is a potential treatment for patients with end-stage heart failure. To understand molecular mechanisms of graft rejection after heart transplantation, we transplanted a 31-day-old alpha-1,3-galactosyltransferase knockout (GTKO) porcine heart to a five-year-old cynomolgus monkey. Histological and transcriptome analyses were conducted on xenografted cardiac tissue at rejection (nine days after transplantation). The recipient monkey’s blood parameters were analyzed on days −7, −3, 1, 4, and 7. Validation was conducted by quantitative real-time PCR (qPCR) with selected genes. A non-transplanted GTKO porcine heart from an age-matched litter was used as a control. The recipient monkey showed systemic inflammatory responses, and the rejected cardiac graft indicated myocardial infarction and cardiac fibrosis. The transplanted heart exhibited a total of 3748 differentially expressed genes compared to the non-transplanted heart transcriptome, with 2443 upregulated and 1305 downregulated genes. Key biological pathways involved at the terminal stage of graft rejection were cardiomyopathies, extracellular interactions, and ion channel activities. The results of qPCR evaluation were in agreement with the transcriptome data. Transcriptome analysis of porcine cardiac tissue at graft rejection reveals dysregulation of the key molecules and signaling pathways, which play relevant roles on structural and functional integrities of the heart.
- 9 November 2020
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 32 (1) , 199-210
Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults
Significance Statement: Steroid resistance, relapse, and side effects are common issues in use of high-dose steroids as first-line treatment for adult minimal change nephrotic syndrome. Tacrolimus is used as a steroid-sparing immunosuppressant to reduce adverse effects of long-term or repeated steroid treatment, but no large-scale randomized study has compared combined tacrolimus and low-dose steroid with high-dose steroid in treating minimal change nephrotic syndrome in adults. In this open-label randomized trial, the authors found that treatment with tacrolimus plus low-dose steroid was noninferior to high-dose steroid for complete remission at 8 weeks, and that treatment with a maintenance dose of tacrolimus during steroid tapering reduced the relapse rate, with no clinically-relevant safety differences. This indicates that tacrolimus is an effective alternative to high-dose steroids in this disease, although investigation into long-term safety is warranted. Background: Tacrolimus is used as a steroid-sparing immunosuppressant in adults with minimal change nephrotic syndrome. However, combined treatment with tacrolimus and low-dose steroid has not been compared with high-dose steroid for induction of clinical remission in a large-scale randomized study. Methods: In this 24-week open-label noninferiority study, we randomized 144 adults with minimal change nephrotic syndrome to receive 0.05 mg/kg twice-daily tacrolimus plus once-daily 0.5 mg/kg prednisolone, or once-daily 1 mg/kg prednisolone alone, for up to 8 weeks or until achieving complete remission. Two weeks after complete remission, we tapered the steroid to a maintenance dose of 5–7.5 mg/d in both groups until 24 weeks after study drug initiation. The primary end point was complete remission within 8 weeks (urine protein: creatinine ratio 3.0 g/g) after complete remission to within 24 weeks of study drug initiation. Results: Complete remission within 8 weeks occurred in 53 of 67 patients (79.1%) receiving tacrolimus and low-dose steroid and 53 of 69 patients (76.8%) receiving high-dose steroid; this difference demonstrated noninferiority, with an upper confidence limit below the predefined threshold (20%) in both intent-to-treat (11.6%) and per-protocol (17.0%) analyses. Groups did not significantly differ in time until remission. Significantly fewer patients relapsed on maintenance tacrolimus (3–8 ng/ml) plus tapered steroid versus tapered steroid alone (5.7% versus 22.6%, respectively; P=0.01). There were no clinically relevant safety differences. Conclusions: Combined tacrolimus and low-dose steroid was noninferior to high-dose steroid for complete remission induction in adults with minimal change nephrotic syndrome. Relapse rates were significantly lower with maintenance tacrolimus and steroid compared with steroid alone. No clinically-relevant differences in safety findings were observed.
- 9 November 2020
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 32 (1) , 199-210
Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults
Significance Statement: Steroid resistance, relapse, and side effects are common issues in use of high-dose steroids as first-line treatment for adult minimal change nephrotic syndrome. Tacrolimus is used as a steroid-sparing immunosuppressant to reduce adverse effects of long-term or repeated steroid treatment, but no large-scale randomized study has compared combined tacrolimus and low-dose steroid with high-dose steroid in treating minimal change nephrotic syndrome in adults. In this open-label randomized trial, the authors found that treatment with tacrolimus plus low-dose steroid was noninferior to high-dose steroid for complete remission at 8 weeks, and that treatment with a maintenance dose of tacrolimus during steroid tapering reduced the relapse rate, with no clinically-relevant safety differences. This indicates that tacrolimus is an effective alternative to high-dose steroids in this disease, although investigation into long-term safety is warranted. Background: Tacrolimus is used as a steroid-sparing immunosuppressant in adults with minimal change nephrotic syndrome. However, combined treatment with tacrolimus and low-dose steroid has not been compared with high-dose steroid for induction of clinical remission in a large-scale randomized study. Methods: In this 24-week open-label noninferiority study, we randomized 144 adults with minimal change nephrotic syndrome to receive 0.05 mg/kg twice-daily tacrolimus plus once-daily 0.5 mg/kg prednisolone, or once-daily 1 mg/kg prednisolone alone, for up to 8 weeks or until achieving complete remission. Two weeks after complete remission, we tapered the steroid to a maintenance dose of 5–7.5 mg/d in both groups until 24 weeks after study drug initiation. The primary end point was complete remission within 8 weeks (urine protein: creatinine ratio 3.0 g/g) after complete remission to within 24 weeks of study drug initiation. Results: Complete remission within 8 weeks occurred in 53 of 67 patients (79.1%) receiving tacrolimus and low-dose steroid and 53 of 69 patients (76.8%) receiving high-dose steroid; this difference demonstrated noninferiority, with an upper confidence limit below the predefined threshold (20%) in both intent-to-treat (11.6%) and per-protocol (17.0%) analyses. Groups did not significantly differ in time until remission. Significantly fewer patients relapsed on maintenance tacrolimus (3–8 ng/ml) plus tapered steroid versus tapered steroid alone (5.7% versus 22.6%, respectively; P=0.01). There were no clinically relevant safety differences. Conclusions: Combined tacrolimus and low-dose steroid was noninferior to high-dose steroid for complete remission induction in adults with minimal change nephrotic syndrome. Relapse rates were significantly lower with maintenance tacrolimus and steroid compared with steroid alone. No clinically-relevant differences in safety findings were observed.
- Open Access
- 1 November 2020
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 35 (6) , 1291-1304
Renal effects of uric acid: hyperuricemia and hypouricemia
The prevalence of chronic kidney disease (CKD) is increasing worldwide. Although hyperuricemia has been associated with CKD in many studies, it remains controversial whether this is the cause or the result of decreased renal function. Recent observational studies of healthy populations and patients with CKD have reported that uric acid (UA) has an independent role in the development or progression of CKD. Experimental studies have shown several potential mechanisms by which hyperuricemia may cause or promote CKD. However, other reports have indicated an association between hypouricemia and CKD. This opposing effect is hypothesized to occur because UA is a major antioxidant in human plasma and is associated with oxidative stress. In this article, we discuss the potential association between UA imbalance and CKD and how they can be treated.
- 1 November 2020
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 35 (6) , 1291-1304
Open AccessRenal effects of uric acid: hyperuricemia and hypouricemia
The prevalence of chronic kidney disease (CKD) is increasing worldwide. Although hyperuricemia has been associated with CKD in many studies, it remains controversial whether this is the cause or the result of decreased renal function. Recent observational studies of healthy populations and patients with CKD have reported that uric acid (UA) has an independent role in the development or progression of CKD. Experimental studies have shown several potential mechanisms by which hyperuricemia may cause or promote CKD. However, other reports have indicated an association between hypouricemia and CKD. This opposing effect is hypothesized to occur because UA is a major antioxidant in human plasma and is associated with oxidative stress. In this article, we discuss the potential association between UA imbalance and CKD and how they can be treated.
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (28) , e254
Association between Serum Uric Acid Level and ESRD or Death in a Korean Population
Kim K, et al. J Korean Med Sci. 2020 Jun;35(28):e254. https://doi.org/10.3346/jkms.2020.35.e254
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (28) , e254
Open AccessAssociation between Serum Uric Acid Level and ESRD or Death in a Korean Population
Kim K, et al. J Korean Med Sci. 2020 Jun;35(28):e254. https://doi.org/10.3346/jkms.2020.35.e254
- Open Access
- 1 July 2018
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 33 (4) , 660-669
Clinical usefulness of bioimpedance analysis for assessing volume status in patients receiving maintenance dialysis
Chronic volume overload is associated with left ventricular hypertrophy and high cardiovascular mortality in patients undergoing dialysis. Therefore, estimating body fluid status is important in these patients. However, most dry-weight assessments are still performed clinically, while attempts have been made to measure the volume status and dry weight of patients undergoing dialysis using bioimpedance analysis (BIA). BIA uses the electrical properties of the human body to alternate current flow and measures resistance values to estimate body water content and composition. BIA is divided into single-frequency BIA, multi-frequency BIA, and bioimpedance spectroscopy (BIS) according to the number of frequencies used, and into whole-body and segmental BIA according to whether or not the whole body is divided into segments. Extracellular water (ECW), intracellular water, and total body water (TBW) contents can be measured with BIA. Dry weight can be estimated by measuring the volume overload of the patient through the ECW/TBW and ECW-to-body weight ratios. Other estimation methods include the normovolemia/hypervolemia slope method, a resistance-reactance (RXc) graph, overhydration measurements using a body composition monitor, and calf BIS. In this review, we will examine the principles of BIA, introduce various volume status measurement methods, and identify the optimal method for patients undergoing dialysis.
- 1 July 2018
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 33 (4) , 660-669
Open AccessClinical usefulness of bioimpedance analysis for assessing volume status in patients receiving maintenance dialysis
Chronic volume overload is associated with left ventricular hypertrophy and high cardiovascular mortality in patients undergoing dialysis. Therefore, estimating body fluid status is important in these patients. However, most dry-weight assessments are still performed clinically, while attempts have been made to measure the volume status and dry weight of patients undergoing dialysis using bioimpedance analysis (BIA). BIA uses the electrical properties of the human body to alternate current flow and measures resistance values to estimate body water content and composition. BIA is divided into single-frequency BIA, multi-frequency BIA, and bioimpedance spectroscopy (BIS) according to the number of frequencies used, and into whole-body and segmental BIA according to whether or not the whole body is divided into segments. Extracellular water (ECW), intracellular water, and total body water (TBW) contents can be measured with BIA. Dry weight can be estimated by measuring the volume overload of the patient through the ECW/TBW and ECW-to-body weight ratios. Other estimation methods include the normovolemia/hypervolemia slope method, a resistance-reactance (RXc) graph, overhydration measurements using a body composition monitor, and calf BIS. In this review, we will examine the principles of BIA, introduce various volume status measurement methods, and identify the optimal method for patients undergoing dialysis.
- 19 December 2015
- Published by Science and Engineering Research Support Society
- p. 603-606
What is “Outline Signal Teaching Method”?
- 19 December 2015
- Published by Science and Engineering Research Support Society
- p. 603-606
What is “Outline Signal Teaching Method”?
- Open Access
- 1 January 2014
- Published by XMLink in Journal of Korean Medical Science
- Vol. 29 (Suppl 2) , S97-S102
Estimating 24-Hour Urine Sodium Level with Spot Urine Sodium and Creatinine
Koo HS, et al. J Korean Med Sci. 2014 Sep;29(Suppl 2):S97-S102. https://doi.org/10.3346/jkms.2014.29.S2.S97
- 1 January 2014
- Published by XMLink in Journal of Korean Medical Science
- Vol. 29 (Suppl 2) , S97-S102
Open AccessEstimating 24-Hour Urine Sodium Level with Spot Urine Sodium and Creatinine
Koo HS, et al. J Korean Med Sci. 2014 Sep;29(Suppl 2):S97-S102. https://doi.org/10.3346/jkms.2014.29.S2.S97
- Open Access
- 1 January 2014
- Published by XMLink in Journal of Korean Medical Science
- Vol. 29 (Suppl 2) , S131-S138
Estimated Amount of 24-Hour Urine Sodium Excretion Is Positively Correlated with Stomach and Breast Cancer Prevalence in Korea
Park JH, et al. J Korean Med Sci. 2014 Sep;29(Suppl 2):S131-S138. http://dx.doi.org/10.3346/jkms.2014.29.S2.S131
- 1 January 2014
- Published by XMLink in Journal of Korean Medical Science
- Vol. 29 (Suppl 2) , S131-S138
Open AccessEstimated Amount of 24-Hour Urine Sodium Excretion Is Positively Correlated with Stomach and Breast Cancer Prevalence in Korea
Park JH, et al. J Korean Med Sci. 2014 Sep;29(Suppl 2):S131-S138. http://dx.doi.org/10.3346/jkms.2014.29.S2.S131